Diabetes drug may decrease COVID-19 death risk in women

358

ISLAMABAD, December 10 (online): A recent study found an association between metformin and a significantly reduced mortality risk in women with type 2 diabetes or obesity who were hospitalized with COVID-19.
Metformin is a first-line medication for treating type 2 diabetes, and many in the United States use the branded version Glucophage.

The results of the recent investigation into metformin use, obesity, diabetes risk, and COVID-19 mortality appear in The Lancet Healthy Longevity.
In the week ending November 28, 2020, the cumulative COVID-19 hospitalization rate in the United States reached a new peak.
The reported mortality rate due to pneumonia, influenza, and COVID-19 was 12.8%, though the receipt of additional data is likely to increase this figure.
Metformin, a safe, effective, relatively inexpensive drug, elevates anti-inflammatory IL-10 levels while decreasing the inflammatory markers TNF-α and IL-6 in people with or without diabetes.
Due to metformin’s anti-inflammatory effects and early reports of decreased COVID-19 mortality rates in people taking the drug, researchers at the University of Minnesota Medical School, in Minneapolis, and UnitedHealth Group (UHG), in Miami, FL, decided to investigate whether metformin decreased COVID-19 death risk — and whether any reduction would be sex-specific.
They refer, in their study paper, to previous findings that metformin reduced inflammation to a greater extent in women than in men.
Ends/Online